핵의학

본문글자크기
  • [Nucl Med Commun.] Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.

    2017년 01월호
    [Nucl Med Commun.] Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.

    KIRAMS / 황재필, 임일한*

  • 출처
    Nucl Med Commun.
  • 등재일
    2016 Dec
  • 저널이슈번호
    37(12):1267-1272.
  • 내용

    바로가기  >



    Abstract

    PURPOSE:

    The aim of this retrospective study was to determine whether glucose metabolism assessed by fluorine-18 fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) provides prognostic information independent of established prognostic factors in patients with gastric lymphoma.


    PATIENTS AND METHODS:

    We reviewed the medical records of 86 patients retrospectively (men, 42; women, 44; mean age 58±13 years) with pathologically proven gastric lymphoma (34 mucosa-associated lymphoid tissue and 52 aggressive non-Hodgkin's lymphoma). They underwent F-FDG PET/CT as part of a pretreatment work-up from February 2004 to July 2012. For the analysis, patients were classified by age, sex, Musshoff stage, serum lactate dehydrogenase, International Prognostic Index score, extragastric spread, and visual intensity [visual assessment and maximum standardized uptake value (SUVmax), respectively]. The relationship between F-FDG uptake and survival was analyzed using the Kaplan-Meier method with a log-rank test and Cox's proportional-hazard regression method.


    RESULTS:

    The median survival of all 86 study participants was 1117 days and the median SUV measured by PET/CT was 6.1 (range, 1.9-32.7). Patients with an SUVmax less than or equal to 5.2 survived significantly longer than patients with an SUVmax more than 5.2 (median, 1163 vs. 1004 days; P=0.003). Survival was also found to be significantly related to age (P=0.0005), histological type (P=0.004), extragastric spread (P=0.0004), International Prognostic Index score (P<0.0001), serum lactate dehydrogenase (P=0.02), stage (P<0.0001), and visual intensity (P=0.041). A multivariate analysis showed that patients with a higher SUVmax [P=0.021; 95% confidence interval (CI), 1.52-8.14; hazard ratio (HR)=6.29], older age (P=0.001; 95% CI, 4.64-219.96; HR=18.8), more aggressive histologic type (P=0.006; 95% CI, 2.20-70.63; HR=12.76), and higher stage (P=0.0006; 95% CI, 5.81-206.43; HR=17.48) showed worse survival.


    CONCLUSION:

    A higher SUVmax on pretreatment F-FDG PET/CT can predict poorer survival in patients with gastric lymphoma.​ 

     

    Author information

    Hwang JP1, Lim I, Byun BH, Kim BI, Choi CW, Lim SM.

    1aDepartment of Nuclear Medicine bMolecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea. 

  • 연구소개
    전반적인 lymphoma의 경우 치료전 병기설정과 치료반응평가에 이미 FDG PET/CT가 적극적으로 사용되고 있습니다. 우리는 위에 발생한 원발성 위림프종에 초점을 맞추어 치료전 표준화섭취계수가 높을수록 예후가 나빠짐을 확인하였습니다. 또한 이미 알려진 예후인자인 높은 병기, 노령, 공격적인 조직형의 의미도 재확인 하였으며, 이에 더하여 FDG PET/CT의 metabolic parameter가 임상의들의 최적의 치료계획 설정에 도움이 될 것이라 생각됩니다.
  • 덧글달기
    덧글달기
       IP : 3.145.174.57

    등록